| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antipsychotic Agents | 22 | 2025 | 381 | 3.620 |
Why?
|
| Antidepressive Agents | 15 | 2025 | 327 | 3.070 |
Why?
|
| Depressive Disorder, Major | 17 | 2025 | 453 | 2.980 |
Why?
|
| Piperazines | 10 | 2025 | 255 | 2.370 |
Why?
|
| Schizophrenia | 14 | 2025 | 332 | 2.180 |
Why?
|
| Bipolar Disorder | 14 | 2025 | 369 | 2.090 |
Why?
|
| Coronary Vessel Anomalies | 14 | 2023 | 289 | 1.860 |
Why?
|
| Computed Tomography Angiography | 15 | 2025 | 215 | 1.820 |
Why?
|
| Liver Diseases | 9 | 2023 | 385 | 1.770 |
Why?
|
| Cystic Fibrosis | 6 | 2023 | 264 | 1.310 |
Why?
|
| Hepatoblastoma | 9 | 2023 | 183 | 1.200 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2023 | 93 | 1.140 |
Why?
|
| Liver Neoplasms | 13 | 2023 | 1381 | 1.130 |
Why?
|
| Ketamine | 4 | 2022 | 226 | 0.960 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 3 | 2022 | 128 | 0.940 |
Why?
|
| Drug Substitution | 1 | 2025 | 20 | 0.940 |
Why?
|
| Renal Artery Obstruction | 2 | 2021 | 42 | 0.870 |
Why?
|
| Liver | 10 | 2023 | 1797 | 0.860 |
Why?
|
| Paroxetine | 7 | 2009 | 25 | 0.860 |
Why?
|
| Health Resources | 1 | 2025 | 135 | 0.850 |
Why?
|
| Quinolones | 3 | 2017 | 58 | 0.820 |
Why?
|
| Rhabdomyoma | 1 | 2022 | 15 | 0.770 |
Why?
|
| Humans | 132 | 2025 | 132247 | 0.750 |
Why?
|
| Coronary Angiography | 11 | 2025 | 487 | 0.740 |
Why?
|
| Health Care Costs | 1 | 2025 | 415 | 0.730 |
Why?
|
| Heart Neoplasms | 1 | 2022 | 105 | 0.710 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2023 | 3853 | 0.700 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 124 | 0.700 |
Why?
|
| Psychotic Disorders | 4 | 2007 | 150 | 0.660 |
Why?
|
| Psychotropic Drugs | 4 | 2018 | 129 | 0.660 |
Why?
|
| Thiazoles | 4 | 2015 | 99 | 0.630 |
Why?
|
| Child | 49 | 2025 | 25783 | 0.580 |
Why?
|
| Vascular Malformations | 5 | 2022 | 112 | 0.560 |
Why?
|
| Mental Health | 1 | 2021 | 377 | 0.560 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 767 | 0.550 |
Why?
|
| Coronary Artery Disease | 5 | 2023 | 893 | 0.540 |
Why?
|
| Psychomotor Agitation | 1 | 2017 | 57 | 0.520 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2024 | 274 | 0.520 |
Why?
|
| Myocardial Perfusion Imaging | 7 | 2024 | 57 | 0.510 |
Why?
|
| Jejunal Diseases | 1 | 2016 | 14 | 0.510 |
Why?
|
| Male | 67 | 2025 | 65014 | 0.510 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2009 | 223 | 0.500 |
Why?
|
| Colonic Diseases | 1 | 2016 | 38 | 0.490 |
Why?
|
| Fistula | 1 | 2016 | 54 | 0.490 |
Why?
|
| Coronary Vessels | 6 | 2023 | 549 | 0.490 |
Why?
|
| Drug Discovery | 1 | 2017 | 174 | 0.480 |
Why?
|
| Mental Disorders | 3 | 2021 | 893 | 0.480 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 97 | 0.470 |
Why?
|
| Dibenzothiazepines | 1 | 2015 | 12 | 0.460 |
Why?
|
| Female | 64 | 2025 | 70787 | 0.460 |
Why?
|
| Myocardial Ischemia | 3 | 2023 | 341 | 0.450 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 403 | 0.440 |
Why?
|
| Adult | 37 | 2025 | 31614 | 0.440 |
Why?
|
| Treatment Outcome | 31 | 2025 | 13027 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2022 | 1249 | 0.420 |
Why?
|
| Aorta, Thoracic | 4 | 2021 | 540 | 0.420 |
Why?
|
| Psychiatric Status Rating Scales | 12 | 2025 | 855 | 0.420 |
Why?
|
| Sarcoma | 1 | 2016 | 207 | 0.420 |
Why?
|
| Contrast Media | 7 | 2025 | 507 | 0.370 |
Why?
|
| Drug Therapy, Combination | 6 | 2025 | 1177 | 0.370 |
Why?
|
| Aorta | 8 | 2023 | 552 | 0.360 |
Why?
|
| Depression | 5 | 2022 | 1350 | 0.360 |
Why?
|
| Double-Blind Method | 14 | 2025 | 1653 | 0.350 |
Why?
|
| Magnetic Resonance Imaging, Cine | 4 | 2023 | 175 | 0.350 |
Why?
|
| Argininosuccinate Lyase | 2 | 2021 | 65 | 0.320 |
Why?
|
| Patient Compliance | 4 | 2007 | 473 | 0.320 |
Why?
|
| Middle Aged | 27 | 2025 | 29021 | 0.320 |
Why?
|
| Heart Defects, Congenital | 5 | 2025 | 1866 | 0.320 |
Why?
|
| Aripiprazole | 3 | 2017 | 22 | 0.320 |
Why?
|
| Prospective Studies | 15 | 2024 | 6568 | 0.310 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 2022 | 145 | 0.310 |
Why?
|
| Anxiety Disorders | 3 | 2009 | 734 | 0.310 |
Why?
|
| Patient Care Team | 3 | 2020 | 576 | 0.300 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2006 | 11 | 0.300 |
Why?
|
| Retrospective Studies | 24 | 2023 | 17395 | 0.300 |
Why?
|
| Health Status | 3 | 2022 | 408 | 0.290 |
Why?
|
| Adolescent | 26 | 2024 | 20557 | 0.290 |
Why?
|
| Heart Ventricles | 3 | 2023 | 785 | 0.280 |
Why?
|
| Delayed-Action Preparations | 10 | 2017 | 122 | 0.280 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 984 | 0.280 |
Why?
|
| Cardiac-Gated Imaging Techniques | 2 | 2025 | 8 | 0.270 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2009 | 36 | 0.270 |
Why?
|
| Child, Preschool | 19 | 2022 | 14736 | 0.260 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 313 | 0.250 |
Why?
|
| Infant | 17 | 2023 | 13049 | 0.250 |
Why?
|
| Central Nervous System Stimulants | 3 | 2016 | 128 | 0.250 |
Why?
|
| Selegiline | 1 | 2006 | 7 | 0.250 |
Why?
|
| Cyclohexanols | 2 | 2003 | 9 | 0.250 |
Why?
|
| Embolization, Therapeutic | 3 | 2021 | 223 | 0.240 |
Why?
|
| Synaptic Transmission | 2 | 2018 | 332 | 0.230 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 43 | 0.230 |
Why?
|
| Anhedonia | 1 | 2025 | 36 | 0.230 |
Why?
|
| Insurance Claim Review | 1 | 2025 | 27 | 0.230 |
Why?
|
| Metabolic Syndrome | 2 | 2007 | 365 | 0.230 |
Why?
|
| Mood Disorders | 3 | 2022 | 129 | 0.230 |
Why?
|
| Hemangioendothelioma | 2 | 2022 | 25 | 0.230 |
Why?
|
| Aged | 11 | 2019 | 21482 | 0.220 |
Why?
|
| Postoperative Complications | 5 | 2021 | 3139 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2023 | 2166 | 0.220 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.220 |
Why?
|
| Predictive Value of Tests | 8 | 2023 | 2314 | 0.220 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 1307 | 0.220 |
Why?
|
| Young Adult | 9 | 2025 | 9966 | 0.220 |
Why?
|
| Liver Transplantation | 4 | 2018 | 1102 | 0.220 |
Why?
|
| Exercise | 2 | 2021 | 860 | 0.220 |
Why?
|
| Fibromyalgia | 3 | 2009 | 21 | 0.220 |
Why?
|
| Depressive Disorder | 2 | 2009 | 481 | 0.220 |
Why?
|
| Interleukin-15 | 1 | 2024 | 96 | 0.210 |
Why?
|
| Cardiac Catheterization | 4 | 2024 | 671 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2025 | 144 | 0.210 |
Why?
|
| Myocardial Bridging | 1 | 2024 | 14 | 0.210 |
Why?
|
| Metabolic Diseases | 1 | 2005 | 139 | 0.210 |
Why?
|
| Schizophrenic Psychology | 2 | 2017 | 85 | 0.210 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 1966 | 0.210 |
Why?
|
| Surveys and Questionnaires | 8 | 2022 | 3995 | 0.200 |
Why?
|
| Informed Consent | 3 | 2008 | 346 | 0.200 |
Why?
|
| Replantation | 2 | 2021 | 56 | 0.200 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 55 | 0.200 |
Why?
|
| Heart Diseases | 2 | 2025 | 511 | 0.200 |
Why?
|
| Stenosis, Pulmonary Vein | 1 | 2023 | 24 | 0.200 |
Why?
|
| Pandemics | 2 | 2021 | 1186 | 0.200 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2021 | 85 | 0.200 |
Why?
|
| Clinical Trials as Topic | 5 | 2017 | 1161 | 0.200 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2002 | 12 | 0.200 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2023 | 44 | 0.200 |
Why?
|
| Mianserin | 1 | 2002 | 3 | 0.200 |
Why?
|
| Liver Cirrhosis | 4 | 2023 | 898 | 0.200 |
Why?
|
| Colonic Diseases, Functional | 1 | 2002 | 26 | 0.200 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 3093 | 0.190 |
Why?
|
| Surface Plasmon Resonance | 1 | 2022 | 53 | 0.190 |
Why?
|
| Bupropion | 1 | 2002 | 29 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 420 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2017 | 2851 | 0.190 |
Why?
|
| Chronic Disease | 2 | 2020 | 1233 | 0.190 |
Why?
|
| Angiography | 4 | 2023 | 208 | 0.190 |
Why?
|
| Aging | 2 | 2019 | 1254 | 0.180 |
Why?
|
| Ductus Arteriosus | 1 | 2022 | 62 | 0.180 |
Why?
|
| Administration, Intranasal | 1 | 2022 | 140 | 0.180 |
Why?
|
| Adenosine A2 Receptor Agonists | 2 | 2019 | 12 | 0.180 |
Why?
|
| Aneurysm, False | 1 | 2023 | 93 | 0.180 |
Why?
|
| Yttrium Radioisotopes | 1 | 2021 | 19 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2004 | 277 | 0.180 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2022 | 76 | 0.180 |
Why?
|
| Hypertension, Portal | 1 | 2022 | 78 | 0.180 |
Why?
|
| Triazoles | 1 | 2002 | 147 | 0.180 |
Why?
|
| Purines | 2 | 2019 | 113 | 0.180 |
Why?
|
| Renal Artery | 1 | 2021 | 69 | 0.180 |
Why?
|
| Prognosis | 5 | 2023 | 5016 | 0.170 |
Why?
|
| Receptors, sigma | 2 | 2017 | 6 | 0.170 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2020 | 4 | 0.170 |
Why?
|
| Radiology Department, Hospital | 1 | 2020 | 25 | 0.170 |
Why?
|
| Liver Glycogen | 1 | 2020 | 22 | 0.160 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2019 | 9 | 0.160 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 20 | 0.160 |
Why?
|
| Twins, Conjoined | 1 | 2020 | 30 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 68 | 0.160 |
Why?
|
| Ultrasonography | 4 | 2021 | 988 | 0.160 |
Why?
|
| Norwood Procedures | 1 | 2021 | 105 | 0.160 |
Why?
|
| Models, Anatomic | 1 | 2020 | 104 | 0.160 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2019 | 23 | 0.150 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 16 | 0.150 |
Why?
|
| Neurosciences | 1 | 2019 | 52 | 0.150 |
Why?
|
| Positive-Pressure Respiration | 1 | 2019 | 85 | 0.150 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2019 | 98 | 0.150 |
Why?
|
| Pyrazoles | 2 | 2019 | 329 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2002 | 447 | 0.150 |
Why?
|
| Heart Arrest | 1 | 2023 | 375 | 0.150 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 149 | 0.150 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 73 | 0.140 |
Why?
|
| Cystine Depleting Agents | 1 | 2018 | 2 | 0.140 |
Why?
|
| Lymphography | 1 | 2018 | 13 | 0.140 |
Why?
|
| Cysteamine | 1 | 2018 | 15 | 0.140 |
Why?
|
| Infant, Newborn | 8 | 2020 | 8548 | 0.140 |
Why?
|
| Lymphatic Diseases | 1 | 2018 | 31 | 0.140 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 25 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 902 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 121 | 0.140 |
Why?
|
| Paliperidone Palmitate | 1 | 2017 | 4 | 0.140 |
Why?
|
| Methylphenidate | 2 | 2009 | 58 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2024 | 899 | 0.140 |
Why?
|
| Mental Competency | 1 | 1998 | 53 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 396 | 0.140 |
Why?
|
| Umbilical Veins | 1 | 2017 | 68 | 0.140 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2021 | 271 | 0.140 |
Why?
|
| Coronary Sinus | 1 | 2017 | 13 | 0.140 |
Why?
|
| Drug Evaluation | 1 | 2017 | 106 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2020 | 304 | 0.130 |
Why?
|
| Hemangioma | 1 | 2018 | 97 | 0.130 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 1170 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2024 | 1175 | 0.130 |
Why?
|
| Dopamine Antagonists | 1 | 2017 | 39 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 207 | 0.130 |
Why?
|
| Serotonin Agents | 1 | 2017 | 15 | 0.130 |
Why?
|
| Quality of Life | 3 | 2022 | 2161 | 0.130 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2017 | 23 | 0.130 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2006 | 831 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2021 | 459 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 5410 | 0.130 |
Why?
|
| Hepatectomy | 3 | 2023 | 118 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.130 |
Why?
|
| Image Enhancement | 1 | 2018 | 173 | 0.130 |
Why?
|
| Chest Pain | 1 | 2017 | 128 | 0.130 |
Why?
|
| Thiophenes | 1 | 2017 | 69 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2019 | 197 | 0.130 |
Why?
|
| Hospitalization | 1 | 2025 | 1902 | 0.130 |
Why?
|
| Comorbidity | 4 | 2007 | 1610 | 0.130 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2019 | 211 | 0.130 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2018 | 225 | 0.120 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2016 | 16 | 0.120 |
Why?
|
| Electroconvulsive Therapy | 1 | 2017 | 82 | 0.120 |
Why?
|
| Exercise Test | 3 | 2024 | 256 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2018 | 280 | 0.120 |
Why?
|
| Gastroscopy | 1 | 2016 | 102 | 0.120 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 68 | 0.120 |
Why?
|
| Child Abuse | 2 | 2009 | 204 | 0.120 |
Why?
|
| Drug Interactions | 3 | 2008 | 246 | 0.120 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2016 | 81 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1757 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2015 | 11 | 0.120 |
Why?
|
| Adenoma, Liver Cell | 1 | 2015 | 4 | 0.120 |
Why?
|
| Hernia, Abdominal | 1 | 2015 | 18 | 0.120 |
Why?
|
| Quetiapine Fumarate | 1 | 2015 | 14 | 0.110 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2009 | 92 | 0.110 |
Why?
|
| Pain Measurement | 4 | 2009 | 352 | 0.110 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 20 | 0.110 |
Why?
|
| Aggression | 1 | 2017 | 231 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 390 | 0.110 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 34 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2018 | 308 | 0.110 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2014 | 6 | 0.110 |
Why?
|
| Intestinal Volvulus | 1 | 2015 | 40 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 2 | 2017 | 553 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 315 | 0.110 |
Why?
|
| Respiration | 1 | 2015 | 123 | 0.110 |
Why?
|
| Acetylcarnitine | 1 | 2014 | 3 | 0.110 |
Why?
|
| Risk Factors | 6 | 2020 | 10945 | 0.110 |
Why?
|
| Pneumonectomy | 1 | 2015 | 148 | 0.110 |
Why?
|
| United States | 4 | 2025 | 11669 | 0.110 |
Why?
|
| Isoindoles | 1 | 2013 | 4 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 528 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 1998 | 570 | 0.100 |
Why?
|
| Isoxazoles | 1 | 2013 | 24 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2016 | 236 | 0.100 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 42 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2014 | 45 | 0.100 |
Why?
|
| Stents | 1 | 2020 | 874 | 0.100 |
Why?
|
| Disease Progression | 1 | 2020 | 2233 | 0.100 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2013 | 34 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2016 | 223 | 0.100 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2003 | 19 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 128 | 0.100 |
Why?
|
| Echocardiography | 4 | 2023 | 1126 | 0.100 |
Why?
|
| ROC Curve | 2 | 2014 | 600 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2015 | 148 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2015 | 314 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 201 | 0.100 |
Why?
|
| Appendicitis | 1 | 2014 | 138 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1294 | 0.100 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2017 | 426 | 0.090 |
Why?
|
| Constriction, Pathologic | 2 | 2023 | 235 | 0.090 |
Why?
|
| Imidazoles | 1 | 2013 | 219 | 0.090 |
Why?
|
| Sirolimus | 1 | 2014 | 241 | 0.090 |
Why?
|
| Recurrence | 2 | 2023 | 1453 | 0.090 |
Why?
|
| Child Abuse, Sexual | 2 | 2009 | 34 | 0.090 |
Why?
|
| Piperidines | 1 | 2013 | 235 | 0.090 |
Why?
|
| Weight Gain | 2 | 2006 | 381 | 0.090 |
Why?
|
| Subclavian Artery | 1 | 2012 | 70 | 0.090 |
Why?
|
| Lung | 1 | 2019 | 1556 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 623 | 0.090 |
Why?
|
| Proxy | 1 | 2010 | 21 | 0.090 |
Why?
|
| Republic of Korea | 3 | 2017 | 53 | 0.080 |
Why?
|
| New York | 2 | 2002 | 72 | 0.080 |
Why?
|
| Genotype | 4 | 2018 | 2703 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 6451 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2020 | 3414 | 0.080 |
Why?
|
| Analysis of Variance | 2 | 2009 | 1008 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 2961 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 673 | 0.080 |
Why?
|
| Biomarkers | 4 | 2021 | 3404 | 0.080 |
Why?
|
| Psychophysiologic Disorders | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 3761 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2010 | 219 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 2139 | 0.070 |
Why?
|
| Placebos | 1 | 2009 | 235 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2021 | 381 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2006 | 229 | 0.070 |
Why?
|
| Outpatients | 1 | 2009 | 275 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2015 | 804 | 0.070 |
Why?
|
| Polypharmacy | 1 | 2007 | 37 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 588 | 0.070 |
Why?
|
| Naltrexone | 1 | 2007 | 71 | 0.070 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2007 | 33 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2020 | 3736 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2024 | 861 | 0.070 |
Why?
|
| Cerebral Arteries | 1 | 2007 | 83 | 0.060 |
Why?
|
| Tranylcypromine | 1 | 2006 | 1 | 0.060 |
Why?
|
| Phenelzine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 55 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2006 | 67 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 982 | 0.060 |
Why?
|
| Hyperprolactinemia | 1 | 2005 | 23 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1541 | 0.060 |
Why?
|
| Psychiatry | 1 | 2008 | 272 | 0.060 |
Why?
|
| Alcoholism | 1 | 2007 | 250 | 0.060 |
Why?
|
| Heart | 2 | 2021 | 689 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2005 | 1418 | 0.060 |
Why?
|
| Reoperation | 2 | 2021 | 852 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 5176 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 743 | 0.050 |
Why?
|
| Sleep Wake Disorders | 1 | 2007 | 197 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 1671 | 0.050 |
Why?
|
| Myocardium | 1 | 2009 | 907 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 1288 | 0.050 |
Why?
|
| Buspirone | 1 | 2003 | 13 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2009 | 577 | 0.050 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2003 | 20 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1304 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2003 | 25 | 0.050 |
Why?
|
| Pulmonary Artery | 2 | 2023 | 463 | 0.050 |
Why?
|
| Injections, Intramuscular | 2 | 2017 | 196 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 57 | 0.050 |
Why?
|
| Obesity | 2 | 2005 | 2398 | 0.050 |
Why?
|
| Platelet Count | 1 | 2023 | 139 | 0.050 |
Why?
|
| Self Disclosure | 1 | 2002 | 26 | 0.050 |
Why?
|
| Catheters | 1 | 2023 | 89 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 435 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 551 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 7138 | 0.050 |
Why?
|
| Family | 1 | 2006 | 595 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2018 | 376 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 569 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 106 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2002 | 171 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 172 | 0.040 |
Why?
|
| Dobutamine | 1 | 2021 | 56 | 0.040 |
Why?
|
| Shock, Cardiogenic | 1 | 2023 | 213 | 0.040 |
Why?
|
| Indocyanine Green | 1 | 2021 | 63 | 0.040 |
Why?
|
| Hyperammonemia | 1 | 2021 | 62 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2020 | 52 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2021 | 73 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2020 | 36 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 536 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 821 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 237 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2020 | 26 | 0.040 |
Why?
|
| Movement Disorders | 1 | 2003 | 223 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2020 | 996 | 0.040 |
Why?
|
| Triiodobenzoic Acids | 1 | 2020 | 31 | 0.040 |
Why?
|
| Coronary Stenosis | 1 | 2021 | 83 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2020 | 165 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 52 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2004 | 412 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 53 | 0.040 |
Why?
|
| Perfusion | 1 | 2021 | 208 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2021 | 120 | 0.040 |
Why?
|
| Prolactin | 1 | 2019 | 113 | 0.040 |
Why?
|
| Ischemia | 1 | 2023 | 371 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2004 | 490 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 162 | 0.040 |
Why?
|
| Workplace | 1 | 2020 | 82 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 1444 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 548 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2023 | 515 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2017 | 1574 | 0.040 |
Why?
|
| Prevalence | 1 | 2006 | 2664 | 0.040 |
Why?
|
| Animals | 4 | 2023 | 34854 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 186 | 0.040 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 254 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2018 | 45 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 223 | 0.040 |
Why?
|
| Chylous Ascites | 1 | 2018 | 11 | 0.040 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 605 | 0.040 |
Why?
|
| S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 17 | 0.030 |
Why?
|
| Chylothorax | 1 | 2018 | 28 | 0.030 |
Why?
|
| Ligation | 1 | 2018 | 139 | 0.030 |
Why?
|
| Placebo Effect | 1 | 2017 | 24 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2005 | 1062 | 0.030 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2017 | 56 | 0.030 |
Why?
|
| Survivors | 1 | 2020 | 358 | 0.030 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2017 | 13 | 0.030 |
Why?
|
| Publication Bias | 1 | 2017 | 17 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2018 | 186 | 0.030 |
Why?
|
| Protons | 1 | 2018 | 98 | 0.030 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 2017 | 6 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 306 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 109 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1998 | 80 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 24 | 0.030 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2017 | 42 | 0.030 |
Why?
|
| Psychopathology | 1 | 2017 | 34 | 0.030 |
Why?
|
| Italy | 1 | 2017 | 130 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 216 | 0.030 |
Why?
|
| Herniorrhaphy | 1 | 2017 | 78 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 658 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 144 | 0.030 |
Why?
|
| Transposition of Great Vessels | 1 | 2018 | 135 | 0.030 |
Why?
|
| Palliative Care | 1 | 2021 | 456 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2018 | 244 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 311 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 666 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 161 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 537 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 926 | 0.030 |
Why?
|
| Fibrosis | 1 | 2017 | 421 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1500 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 780 | 0.030 |
Why?
|
| Heart Rate | 1 | 2018 | 584 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 39 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 665 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 1234 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2015 | 50 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 857 | 0.030 |
Why?
|
| Necrosis | 1 | 2015 | 210 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2015 | 119 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 2015 | 60 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2015 | 317 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 326 | 0.030 |
Why?
|
| Dibenzocycloheptenes | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lurasidone Hydrochloride | 1 | 2013 | 3 | 0.030 |
Why?
|
| Patient Discharge | 1 | 1998 | 511 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2015 | 133 | 0.030 |
Why?
|
| Drug Approval | 1 | 2013 | 46 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2923 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 750 | 0.020 |
Why?
|
| Cytokines | 1 | 2019 | 1365 | 0.020 |
Why?
|
| Algorithms | 1 | 2020 | 1725 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 830 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 3376 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2012 | 115 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 1591 | 0.020 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 134 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 348 | 0.020 |
Why?
|
| Intestines | 1 | 2015 | 606 | 0.020 |
Why?
|
| Pregnancy | 3 | 2008 | 7557 | 0.020 |
Why?
|
| Alleles | 1 | 2015 | 1685 | 0.020 |
Why?
|
| Korea | 1 | 2009 | 34 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2009 | 108 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4690 | 0.020 |
Why?
|
| Sick Role | 1 | 2009 | 31 | 0.020 |
Why?
|
| Pediatrics | 1 | 2018 | 1210 | 0.020 |
Why?
|
| Acute Disease | 1 | 2012 | 1163 | 0.020 |
Why?
|
| Ethics Committees, Research | 1 | 2008 | 32 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2008 | 76 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1831 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2008 | 66 | 0.020 |
Why?
|
| South Carolina | 1 | 2007 | 10 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 198 | 0.020 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2007 | 16 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2007 | 13 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2007 | 110 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 166 | 0.020 |
Why?
|
| Middle Cerebral Artery | 1 | 2007 | 115 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4540 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 3358 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2005 | 34 | 0.020 |
Why?
|
| Psychometrics | 1 | 2009 | 693 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 364 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 818 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 635 | 0.010 |
Why?
|
| Poverty | 1 | 2007 | 450 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 749 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 796 | 0.010 |
Why?
|
| Mice | 1 | 2020 | 18509 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 3018 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2005 | 1255 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2007 | 843 | 0.010 |
Why?
|